Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA12 | O43570 | 1/20 | 0.38 |
| ▸ | CA1 | P00915 | 1/20 | 0.38 |
| ▸ | CA2 | P00918 | 1/20 | 0.38 |
| ▸ | CA9 | Q16790 | 1/20 | 0.38 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.38 |
| ▸ | MAPK1 | P28482 | 3/20 | 0.37 |
| ▸ | PKM | P14618 | 2/20 | 0.37 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.37 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.35 |
| ▸ | GAA | P10253 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
| ▸ | PPARG | P37231 | 1/20 | 0.33 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.33 |
| ▸ | CHRNB2 | P17787 | 3/20 | 0.32 |
| ▸ | CHRNA4 | P43681 | 3/20 | 0.32 |
| ▸ | CHRNB4 | P30926 | 2/20 | 0.32 |
| ▸ | CHRNA3 | P32297 | 2/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8694241 | 0.85 | CA12 (0.36) | CA12CA1CA2CA9TDP1 | |
| SCHEMBL451856 | 0.80 | TSHR (0.45) | TDP1LMNAALDH1A1KMT2ASMN1; SMN2 | |
| SCHEMBL697642 | 0.80 | CA1 (0.41) | CA12CA1CA2CA9TDP1 | |
| SCHEMBL452372 | 0.79 | HCAR2 (0.42) | TDP1LMNAALDH1A1KDM4ETSHR | |
| SCHEMBL610682 | 0.79 | CA1 (0.50) | CA12CA1CA2CA9TDP1 | |
| SCHEMBL17075163 | 0.79 | CA1 (0.50) | CA12CA1CA2CA9TDP1 | |
| SCHEMBL451520 | 0.76 | ATM (0.52) | TDP1MAPK1LMNAALDH1A1SMN1; SMN2 | |
| SCHEMBL5511449 | 0.75 | ALDH1A1 (0.59) | CA12CA1CA2CA9TDP1 | |
| SCHEMBL5009623 | 0.75 | CA12 (0.43) | CA12CA1CA2CA9TDP1 | |
| SCHEMBL14311948 | 0.74 | CA1 (0.46) | CA12CA1CA2CA9TDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 77 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-4731362-A | Alkylcarbamoyloxymethylcephem compounds | SHIONOGI & CO., LTD. (JP) | 1988-03-15 | — | — | US | claimed |
| US-9937157-B2 | Modified release dosage forms of xanthine oxidoreductase inhibitor or xanthine oxidase inhibitors | TAKEDA PHARMACEUTICALS U.S.A., INC. (US) | 2018-04-10 | — | — | US | disclosed |
| EP-2582812-B1 | NOVEL MODIFIED RELEASE DOSAGE FORMS OF XANTHINE OXIDOREDUCTASE INHIBITOR OR XANTHINE OXIDASE INHIBITORS | TAKEDA PHARMACEUTICALS USA INC (US) | 2018-01-24 | — | — | EP | disclosed |
| US-20160317505-A1 | NOVEL MODIFIED RELEASE DOSAGE FORMS OF XANTHINE OXIDOREDUCTASE INHIBITOR OR XANTHINE OXIDASE INHIBITORS | TAKEDA PHARMACEUTICALS U.S.A., INC. (US) | 2016-11-03 | — | — | US | disclosed |
| US-9248119-B2 | Modified release dosage forms of xanthine oxidoreductase inhibitor or xanthine oxidase inhibitors | TAKEDA PHARMACEUTICALS U.S.A., INC. (US) | 2016-02-02 | — | — | US | disclosed |
| US-9107912-B2 | Methods for concomitant treatment of theophylline and febuxostat | TAKEDA PHARMACEUTICALS U.S.A., INC. (US) | 2015-08-18 | — | — | US | disclosed |
| EP-2613780-B1 | METHODS FOR CONCOMITANT TREATMENT OF THEOPHYLLINE AND FEBUXOSTAT | TAKEDA PHARMACEUTICALS USA INC (US) | 2014-11-12 | — | — | EP | disclosed |
| US-20140329868-A1 | METHODS FOR TREATING HYPERTENSION | TAKEDA PHARMACEUTICALS USA INC (US) | 2014-11-06 | — | — | US | disclosed |
| US-8586762-B2 | Process for producing fused imidazole compound, reformatsky reagent in stable form, and process for producing the same | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2013-11-19 | — | — | US | disclosed |
| EP-2613780-A1 | METHODS FOR CONCOMITANT TREATMENT OF THEOPHYLLINE AND FEBUXOSTAT | Takeda Pharmaceuticals U.S.A., Inc. (US) | 2013-07-17 | — | — | EP | disclosed |
| US-5084214-A | Compounds for the treatment of artheriosclerosis | SHIONOGI & CO., LTD. (JP) | 1992-01-28 | — | — | US | disclosed |
| EP-0467647-A2 | Thioalkylthio cephalosporin derivatives | SHIONOGI SEIYAKU KABUSHIKI KAISHA trading under the name of SHIONOGI & CO. LTD. (JP) | 1992-01-22 | — | — | EP | disclosed |
| US-5064954-A | Phosphorylation of hydroxymethylcarbapem and halogenation; bactericides | SHIONOGI & CO., LTD. (JP) | 1991-11-12 | — | — | US | disclosed |
| US-5002972-A | Compound and composition of substituted hexenoic acid derivatives useful for treating thromboxane A2 mediated diseases | SHIONOGI & CO., LTD. (JP) | 1991-03-26 | — | — | US | disclosed |
| EP-0415566-A1 | Heterocyclic compounds, processes for producing them and pharmaceutical compositions comprising them | SHIONOGI SEIYAKU KABUSHIKI KAISHA trading under the name of SHIONOGI & CO. LTD. (JP) | 1991-03-06 | — | — | EP | disclosed |
| US-4960880-A | STEREOSPECIFIC SYNTHESIS OF B-LACTAM INTERMEDIATES | SHIONOGI & CO., LTD. (JP) | 1990-10-02 | — | — | US | disclosed |
| EP-0384747-A1 | Pharmaceutical or veterinary preparations of substituted hexenoic acid derivatives | SHIONOGI SEIYAKU KABUSHIKI KAISHA trading under the name of SHIONOGI & CO. LTD. (JP) | 1990-08-29 | — | — | EP | disclosed |
| EP-0348203-A1 | Phenolic thioethers, their production and use | SHIONOGI SEIYAKU KABUSHIKI KAISHA trading under the name of SHIONOGI & CO. LTD. (JP) | 1989-12-27 | — | — | EP | disclosed |
| EP-0308867-A2 | Alkenylsilylazetidinone intermediates for carbapenems | SHIONOGI SEIYAKU KABUSHIKI KAISHA (JP) | 1989-03-29 | — | — | EP | disclosed |
| US-4731362-A | Alkylcarbamoyloxymethylcephem compounds | SHIONOGI & CO., LTD. (JP) | 1988-03-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160317505-A1 | NOVEL MODIFIED RELEASE DOSAGE FORMS OF XANTHINE OXIDOREDUCTASE INHIBITOR OR XANTHINE OXIDASE INHIBITORS | XDH, PNPO, DUOX1 | CA12 4113/4885CA1 3440/4885CA2 1817/4885 |
| US-20140329868-A1 | METHODS FOR TREATING HYPERTENSION | XDH, REN, CYP11B2 | CA12 1619/4885CA1 1237/4885CA2 127/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.